We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: CAR T-cell therapy
MedXY News
EnglishTag

CAR T-cell therapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Five-Year ZUMA-5 Follow-Up: Durable Remissions and Potential for Cure with Axicabtagene Ciloleucel in Relapsed/Refractory Follicular Lymphoma
Hematology-Oncologyaxicabtagene ciloleucelCAR T-cell therapy

Five-Year ZUMA-5 Follow-Up: Durable Remissions and Potential for Cure with Axicabtagene Ciloleucel in Relapsed/Refractory Follicular Lymphoma

By MedXY|Dec 9, 2025

Five-year outcomes from ZUMA-5 show axi-cel produces high response rates in relapsed/refractory indolent NHL, with 75% CR, median PFS ~62 months, durable remissions linked to early CAR T expansion and naïve T-cell product phenotype, and an

Tisagenlecleucel for Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Clinical Outcomes and Long-Term Follow-Up from the JULIET Trial
Clinical UpdatesCAR T-cell therapy
Diffuse large B-cell lymphoma

Tisagenlecleucel for Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Clinical Outcomes and Long-Term Follow-Up from the JULIET Trial

By MedXY|Dec 8, 2025

Tisagenlecleucel CAR T-cell therapy demonstrates durable responses and manageable safety in adults with relapsed or refractory diffuse large B-cell lymphoma, with 5-year data supporting its curative potential in select patients.

Enhancing BCMA-CAR T Cell Therapy in Multiple Myeloma Through Glutamine Metabolism Reprogramming
Hematology-OncologyBCMACAR T-cell therapy

Enhancing BCMA-CAR T Cell Therapy in Multiple Myeloma Through Glutamine Metabolism Reprogramming

By MedXY|Oct 14, 2025

Reprogramming glutamine metabolism via Asct2 transporter expression improves BCMA-CAR T cell fitness, proliferation, and anti-myeloma efficacy under glutamine-limited conditions, offering a promising strategy to overcome metabolic immune ev

Real-World Impact of Cilta-cel versus Ide-cel in CAR T-Cell Therapy for Multiple Myeloma: Insights from the German DRST Registry
Hematology-OncologyCAR T-cell therapyCiltacabtagene autoleucel

Real-World Impact of Cilta-cel versus Ide-cel in CAR T-Cell Therapy for Multiple Myeloma: Insights from the German DRST Registry

By MedXY|Oct 14, 2025

A registry analysis in Germany reveals superior remission conversion and progression-free survival with ciltacabtagene autoleucel compared to idecabtagene vicleucel in heavily pretreated multiple myeloma, supporting individualized CAR T the

Advancing Treatment in Relapsed/Refractory Plasma Cell Myeloma: Dual-Nanobody BCMA CAR T-Cell Therapy Shows Promising Efficacy and Safety
Hematology-OncologyBCMACAR T-cell therapy

Advancing Treatment in Relapsed/Refractory Plasma Cell Myeloma: Dual-Nanobody BCMA CAR T-Cell Therapy Shows Promising Efficacy and Safety

By MedXY|Oct 8, 2025

Nanobody-based dual-targeting BCMA CAR T-cell therapy demonstrates high response rates and manageable safety in relapsed/refractory plasma cell myeloma, including high-risk subgroups.

Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up
Clinical UpdatesCAR T-cell therapyLarge B-Cell Lymphoma

Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up

By MedXY|Oct 7, 2025

The 3-year follow-up of the phase III TRANSFORM study demonstrates that lisocabtagene maraleucel (liso-cel) provides superior durable efficacy and a favorable safety profile compared with standard of care in second-line relapsed/refractory

Clonal Hematopoiesis and Its Link to Severe Cytokine Release Syndrome in CAR T-Cell Therapy Recipients
Allergy & ImmunologyCAR T-cell therapyClonal hematopoiesis

Clonal Hematopoiesis and Its Link to Severe Cytokine Release Syndrome in CAR T-Cell Therapy Recipients

By MedXY|Oct 5, 2025

Clonal hematopoiesis (CH) occurs frequently in patients receiving CD19 or BCMA CAR T therapy and correlates with a higher risk of severe cytokine release syndrome (CRS), suggesting CH as a potential biomarker for CRS risk and a target for p

Tandem CD19/CD22 CAR T-Cell Therapy: A Promising Advance for High-Risk Pediatric and AYA r/r B-ALL
Hematology-OncologyB-ALLCAR T-cell therapy

Tandem CD19/CD22 CAR T-Cell Therapy: A Promising Advance for High-Risk Pediatric and AYA r/r B-ALL

By MedXY|Oct 5, 2025

Tandem CD19/CD22 CAR T-cell therapy shows encouraging safety and efficacy in heavily pretreated children and young adults with relapsed/refractory B-ALL, particularly when combined with consolidative hematopoietic stem cell transplantation.

T-ICAHT: A New Grading System for Thrombocytopenia After CAR T-cell Therapy with Prognostic Significance
Hematology-OncologyB-cell lymphomaCAR T-cell therapy

T-ICAHT: A New Grading System for Thrombocytopenia After CAR T-cell Therapy with Prognostic Significance

By MedXY|Oct 5, 2025

A novel grading system, T-ICAHT, quantifies thrombocytopenia after CAR T-cell therapy, revealing its prevalence and prognostic impact, highlighting its value in patient management and outcome prediction across hematologic malignancies.

ZUMA-8 Trial: Advancing CAR T-Cell Therapy with Brexucabtagene Autoleucel in Relapsed/Refractory Chronic Lymphocytic Leukemia
Clinical UpdatesCAR T-cell therapy

ZUMA-8 Trial: Advancing CAR T-Cell Therapy with Brexucabtagene Autoleucel in Relapsed/Refractory Chronic Lymphocytic Leukemia

By MedXY|Oct 5, 2025

The ZUMA-8 phase 1 study evaluates the safety and efficacy of brexucabtagene autoleucel, a CD19-directed CAR T-cell therapy, in relapsed/refractory CLL, showing promising response rates and manageable safety profiles, especially in patients

Lisocabtagene Maraleucel Shows Durable Superior Efficacy Over Standard Therapy in Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year TRANSFORM Study Follow-Up
Hematology-OncologyCAR T-cell therapyLarge B-Cell Lymphoma

Lisocabtagene Maraleucel Shows Durable Superior Efficacy Over Standard Therapy in Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year TRANSFORM Study Follow-Up

By MedXY|Oct 4, 2025

Three-year follow-up from the phase III TRANSFORM trial confirms lisocabtagene maraleucel (liso-cel) significantly improves event-free survival and response durability over standard of care in second-line relapsed/refractory large B-cell ly

Prev
2 / 2
12
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities